Moderna Given Sell Rating at Deutsche Bank. The Stock Is Falling.

Moderna was under pressure Friday after Deutsche Bank called the Covid-19 vaccine maker a “concept stock,” giving shares in the biotech a Sell rating and price target 34% below the stock’s previous closing price.

Deutsche Bank’s Emmanuel Papadakis initiated coverage of Moderna (ticker: MRNA) with a Sell rating on the shares and a target price of $225.


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button